title: Antigen presentation under the influence of 'immune evasion' proteins and its modulation by interferon-gamma: implications for immunotherapy of cytomegalovirus infection with antiviral CD8 T cells.
abstract: Cytomegalovirus (CMV) disease with multiple organ manifestations is the most feared viral complication limiting the success of hematopoietic cell transplantation as a therapy of hematopoietic malignancies. A timely endogenous reconstitution of CD8 T cells controls CMV infection, and adoptive transfer of antiviral CD8 T cells is a therapeutic option to prevent CMV disease by bridging the gap between an early CMV reactivation and delayed endogenous reconstitution of protective immunity. Preclinical research in murine models has provided 'proof of concept' for CD8 T-cell therapy of CMV disease. Protection by CD8 T cells appears to be in conflict with the finding that CMVs encode proteins that inhibit antigen presentation to CD8 T cells by interfering with the constitutive trafficking of peptide-loaded MHC class I molecules (pMHC-I complexes) to the cell surface. Here, we have systematically explored antigen presentation in the presence of the three currently noted immune evasion proteins of murine CMV in all possible combinations and its modulation by pre-treatment of cells with interferon-gamma (IFN-γ). The data reveal improvement in antigen processing by pre-treatment with IFN-γ can almost overrule the inhibitory function of immune evasion molecules in terms of pMHC-I expression levels capable of triggering most of the specific CD8 T cells, though the intensity of stimulation did not retrieve their full functional capacity. Notably, an in vivo conditioning of host tissue cells with IFN-γ in adoptive cell transfer recipients constitutively overexpressing IFN-γ (B6-SAP-IFN-γ mice) enhanced the antiviral efficiency of CD8 T cells in this transgenic cytoimmunotherapy model.
authors.affiliation: Institute for Virology, University Medical Center of the Johannes Gutenberg-University Mainz, Obere Zahlbacher Strasse 67, Hochhaus am Augustusplatz, 55131 Mainz, Germany.
authors.forename: Annette
authors.initials: A
authors.lastname: Fink
authors.forename: Niels A W
authors.initials: NA
authors.lastname: Lemmermann
authors.forename: Dorothea
authors.initials: D
authors.lastname: Gillert-Marien
authors.forename: Doris
authors.initials: D
authors.lastname: Thomas
authors.forename: Kirsten
authors.initials: K
authors.lastname: Freitag
authors.forename: Verena
authors.initials: V
authors.lastname: Böhm
authors.forename: Vanessa
authors.initials: V
authors.lastname: Wilhelmi
authors.forename: Kurt
authors.initials: K
authors.lastname: Reifenberg
authors.forename: Matthias J
authors.initials: MJ
authors.lastname: Reddehase
authors.forename: Rafaela
authors.initials: R
authors.lastname: Holtappels
mesh_terms: D019264:Adoptive Transfer; D000818:Animals; D017951:Antigen Presentation; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D003587:Cytomegalovirus / Q000276:immunology / Q000472:pathogenicity*; D003586:Cytomegalovirus Infections / Q000276:immunology* / Q000628:therapy; D004195:Disease Models, Animal; D057131:Immune Evasion; D007371:Interferon-gamma / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008822:Mice, Transgenic; D016896:Treatment Outcome
chemical_list: D007371:Interferon-gamma